1. Home
  2. AREN vs SGMT Comparison

AREN vs SGMT Comparison

Compare AREN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AREN
  • SGMT
  • Stock Information
  • Founded
  • AREN 2016
  • SGMT 2006
  • Country
  • AREN United States
  • SGMT United States
  • Employees
  • AREN N/A
  • SGMT N/A
  • Industry
  • AREN Medical/Dental Instruments
  • SGMT
  • Sector
  • AREN Health Care
  • SGMT
  • Exchange
  • AREN Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • AREN 233.1M
  • SGMT 238.7M
  • IPO Year
  • AREN N/A
  • SGMT 2023
  • Fundamental
  • Price
  • AREN $4.93
  • SGMT $9.17
  • Analyst Decision
  • AREN Strong Buy
  • SGMT Strong Buy
  • Analyst Count
  • AREN 1
  • SGMT 8
  • Target Price
  • AREN $12.00
  • SGMT $26.88
  • AVG Volume (30 Days)
  • AREN 218.1K
  • SGMT 480.9K
  • Earning Date
  • AREN 11-13-2025
  • SGMT 11-12-2025
  • Dividend Yield
  • AREN N/A
  • SGMT N/A
  • EPS Growth
  • AREN N/A
  • SGMT N/A
  • EPS
  • AREN 2.74
  • SGMT N/A
  • Revenue
  • AREN $146,610,000.00
  • SGMT N/A
  • Revenue This Year
  • AREN $29.48
  • SGMT N/A
  • Revenue Next Year
  • AREN $11.72
  • SGMT N/A
  • P/E Ratio
  • AREN $1.83
  • SGMT N/A
  • Revenue Growth
  • AREN 6.81
  • SGMT N/A
  • 52 Week Low
  • AREN $0.56
  • SGMT $1.73
  • 52 Week High
  • AREN $10.05
  • SGMT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • AREN 48.91
  • SGMT 67.44
  • Support Level
  • AREN $4.19
  • SGMT $7.30
  • Resistance Level
  • AREN $5.10
  • SGMT $8.25
  • Average True Range (ATR)
  • AREN 0.37
  • SGMT 0.69
  • MACD
  • AREN 0.06
  • SGMT 0.11
  • Stochastic Oscillator
  • AREN 91.54
  • SGMT 94.86

About AREN The Arena Group Holdings Inc.

The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: